Table 4.

Effect of Glucose-Lowering Drugs on Heart Failure Hospitalization Risk in Patients with T2DM

Drug ClassMedicationHF Hospitalization
SGLT-2 InhibitorsEmpagliflozin35% reduced risk
Canagliflozin33% reduced risk
Dapagliflozin27% reduced risk
Ertugliflozin30% reduced risk*
Dual SGLT1/SGLT2 InhibitorSotagliflozin33% reduced risk
GLP-1 Receptor AgonistsLiraglutideNeutral effect
LixisenatideNeutral effect
SemaglutideNeutral effect
AlbiglutideNeutral effect
ExenatideNeutral effect
Efpeglenatide39% reduced risk
DPP-4 InhibitorsSaxagliptin27% increased risk
AlogliptinNeutral effect**
SitagliptinNeutral effect
VildagliptinNeutral effect
LinagliptinNeutral effect
ThiazolidinedionesRosiglitazoneIncreased risk***
Pioglitazone41% Increased risk
*

Exploratory secondary outcome (primary outcome of MACE was similar to placebo). **Possible increase in the risk of HF hospitalization in patients without a history of HF at baseline (HR 1.76, 1·07–2·90). *** Increased risk of HF hospitalization and HF-related death (HR 2.10, 1.35-3.27).

From: Diabetes, Cardiomyopathy, and Heart Failure

Cover of Endotext
Endotext [Internet].
Feingold KR, Anawalt B, Blackman MR, et al., editors.
South Dartmouth (MA): MDText.com, Inc.; 2000-.
Copyright © 2000-2024, MDText.com, Inc.

This electronic version has been made freely available under a Creative Commons (CC-BY-NC-ND) license. A copy of the license can be viewed at http://creativecommons.org/licenses/by-nc-nd/2.0/.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.